Q3 2025 GSK plc Earnings Call Transcript
Key Points
- GSK PLC (GSK) reported an 8% increase in total sales for Q3 2025, driven by strong growth in specialty medicines, oncology, and HIV.
- The company upgraded its full-year guidance for sales and profits, reflecting continued strong performance and positive momentum.
- GSK PLC (GSK) achieved four FDA approvals in 2025, with a fifth expected before year-end, showcasing robust R&D progress.
- Cash generation remains strong, with GBP6.3 billion generated year-to-date, supporting growth investments and shareholder returns.
- The company is making significant strides in sustainability, with a low-carbon version of Ventolin expected to launch in 2026, reducing GSK's carbon footprint by up to 45%.
- GSK PLC (GSK) faces challenges from the Medicare redesign in the US, impacting sales, although the effect is expected to be at the lower end of the forecasted range.
- The company is experiencing competitive pressure in the flu vaccine market, particularly in the US, affecting sales growth.
- There is a delay in the start of the CUATRO Phase III study for the Q4M HIV treatment due to supply issues, pushing the timeline to H1 2026.
- The US market for vaccines remains challenging, with slower market uptake in the 60-plus population and lower preseason channel inventory build.
- Despite strong performance, there is a EUR6 billion revenue gap between market expectations for 2031 and GSK PLC (GSK)'s revenue target, primarily in oncology and RI&I.
Ladies and gentlemen, a very warm welcome to the GSK Q3 2025 results call. I'm delighted to be joined today by Emma Walmsley, Luke Miels, Deborah Waterhouse, and Julie Brown, with Tony Wood, David Redfern, joining for Q&A.
Today's call will last approximately one hour, with a presentation taking around 30 minutes and the remaining time for your questions. Please ask only one to two questions so that everyone has a chance to participate.
Before we start, please turn to slide 3. This is the usual Safe Harbor statement. We will comment on our performance using Constant Exchange Rates, or CER, unless otherwise stated.
I will now hand over to Emma on slide 4.
Thank you, and welcome to everybody joining us today. Please turn to the next slide. Our third-quarter results once again demonstrate GSK's continued strong performance with positive momentum driving an upgrade in our guidance for the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
